Biggest reveals from Xbox Developer Direct:
January 19, 2024
Paid plans only.
Link to the original story: https://www.polygon.com/24043387/xbox-developer-direct-showcase-avowed-hellblade-2-indiana-jones
Related Posts
![AI Generated Image](https://bobsnews.altaran.duckdns.org/wp-content/uploads/2023/10/temp_output-345-200x125.png)
How Artificial Intelligence Can Enhance Knowledge Management
**Erasable Programmable Read Only Memory Market** The erasable programmable read-only memory (EPROM) market is expected to grow from $2.3 billion in 2024 to $3.2 billion in 2031. The market is driven by the increasing demand for EPROMs in automotive, industrial, and consumer applications. * **Automotive:** EPROMs are used in automotive applications such as engine control units, anti-lock braking systems, and infotainment systems. The growth of the automotive industry is expected to drive the demand for EPROMs. * **Industrial:** EPROMs are used in industrial applications such as industrial automation, process control, and medical devices. The growth of the industrial sector is expected to drive the demand for EPROMs. * **Consumer:** EPROMs are used in consumer applications such as smart home devices, wearables, and gaming consoles. The growth of the consumer electronics market is expected to drive the demand for EPROMs. The key players in the EPROM market include Micron Technology, Samsung Electronics, and SK Hynix. These companies are expected to continue to invest in research and development in order to develop new and innovative EPROM products.
DCR-STAT3 is a Dicerna Pharmaceuticals drug candidate for the treatment of solid tumors. It is a small interfering RNA (siRNA) that targets the STAT3 gene. STAT3 is a transcription factor that is involved in cell growth and survival. By targeting STAT3, DCR-STAT3 could inhibit the growth and survival of cancer cells. DCR-STAT3 has been shown to be effective in preclinical studies in a variety of solid tumors. In a Phase 1 clinical trial, DCR-STAT3 was well-tolerated and showed promising antitumor activity. A Phase 2 clinical trial is currently underway to evaluate the efficacy and safety of DCR-STAT3 in patients with advanced solid tumors. Based on the available data, DCR-STAT3 has a high likelihood of approval for the treatment of solid tumors.
About The Author
boB
Well, hey there! The name's boB, and I hail from the humble town of boBsville. I'm a bit of a jack-of-all-trades, you know? I enjoy tinkering around with gadgets, exploring the great outdoors, and meeting new people. If you have any questions or just want to chat, feel free to hit me up!